FUNDAMENTALS · Fundamentals · US Healthcare

Pacific Biosciences of California (PACB) Fundamentals 2026 — Revenue Analysis | SniperIQ

Pacific Biosciences of California (PACB) is a US-listed Healthcare company in Medical - Devices with a market capitalization of $433M, trading at

.40 on the NASDAQ. This SniperIQ fundamentals page covers Pacific Biosciences of California's valuation, profitability (net margin -80.3%), revenue (
60M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$433M
Net Margin-80.3%
Revenue (FY25)
60M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Pacific Biosciences of California's market cap?

Pacific Biosciences of California (PACB) has a market capitalization of approximately $433M, trading at

.40 on the NASDAQ. Market cap moves with the live share price.

What is Pacific Biosciences of California's P/E ratio?

Pacific Biosciences of California's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 180.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Pacific Biosciences of California?

Pacific Biosciences of California runs a net profit margin of -80.3%, a gross margin of 37.1%, and an operating margin of -101.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Pacific Biosciences of California generate?

Pacific Biosciences of California reported revenue of

60M for fiscal year 2025, with net income of -$546M and earnings per share (EPS) of -1.82. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Pacific Biosciences of California pay a dividend?

Pacific Biosciences of California does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Pacific Biosciences of California financially healthy?

Pacific Biosciences of California carries a debt-to-equity ratio of 297.29x and a current ratio of 5.65x, with a market beta of 2.29. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Pacific Biosciences of California a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Pacific Biosciences of California (PACB) the key facts are: market cap $433M, revenue

60M, 52-week range 1.09-2.73. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Pacific Biosciences of California's full fundamentals live

Get Pacific Biosciences of California's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Australian Clinical Labs (ACL) fundamentals · Claritev (CTEV) fundamentals · Sirnaomics (2257) fundamentals · Crescent Biopharma (CBIO) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons